Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2). PACAP is now considered to be a potent neurotrophic and neuroprotective peptide. It plays an important role during the embryonic development of the nervous system. PACAP also protects neurons against various toxic insults in neuronal cultures of diverse origins. In vivo, PACAP shows neuroprotection in models of ischemic and traumatic brain injuries, and those of neurodegenerative diseases. The present review summarizes the findings on the neuroprotective potential of PACAP in models of neurodegenerative diseases, with special focus on in vitro and in vivo models of Parkinsons disease, Huntington chorea and Alzheimers disease. Based on these observations, both endogenous and exogenously administered PACAP or its novel analogs, fragments offer a novel therapeutic approach in the treatment of neurodegenerative diseases.
Keywords: PACAP, Parkinson's disease, Huntington chorea, Alzheimer's disease, adenylate, neurodegenerative, glucagon, vasoactive, splicing, phospholipase, ganglia, pathomechanism, nigrostiatal, dopamine, mesencephalon, catecholamine
Current Pharmaceutical Design
Title: Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Volume: 17 Issue: 10
Author(s): D. Reglodi, P. Kiss, A. Lubics and A. Tamas
Affiliation:
Keywords: PACAP, Parkinson's disease, Huntington chorea, Alzheimer's disease, adenylate, neurodegenerative, glucagon, vasoactive, splicing, phospholipase, ganglia, pathomechanism, nigrostiatal, dopamine, mesencephalon, catecholamine
Abstract: Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional peptide exerting its effects via 3 main receptors (PAC1, VPAC1 and VPAC2). PACAP is now considered to be a potent neurotrophic and neuroprotective peptide. It plays an important role during the embryonic development of the nervous system. PACAP also protects neurons against various toxic insults in neuronal cultures of diverse origins. In vivo, PACAP shows neuroprotection in models of ischemic and traumatic brain injuries, and those of neurodegenerative diseases. The present review summarizes the findings on the neuroprotective potential of PACAP in models of neurodegenerative diseases, with special focus on in vitro and in vivo models of Parkinsons disease, Huntington chorea and Alzheimers disease. Based on these observations, both endogenous and exogenously administered PACAP or its novel analogs, fragments offer a novel therapeutic approach in the treatment of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Reglodi D., Kiss P., Lubics A. and Tamas A., Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589355
DOI https://dx.doi.org/10.2174/138161211795589355 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry Elaboration of New Anti-Inflammatory Agents Using Pharmacophore Based 3D QSAR of 4, 5-Diaryl Imidazoline as P2X7 Receptor Antagonists
Letters in Drug Design & Discovery Fenofibrate Increases Heme Oxygenase 1 Expression and Astrocyte Proliferation While Limits Neuronal Injury During Intracerebral Hemorrhage
Current Neurovascular Research Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research Emerging Therapies for Type 2 Diabetes
Current Drug Therapy Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology Strategies to Improve Bioavailability and <i>In Vivo</i> Efficacy of the Endogenous Opioid Peptides Endomorphin-1 and Endomorphin-2
Current Topics in Medicinal Chemistry A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Electroacupuncture Reduces Hemiplegia Following Acute Middle Cerebral Artery Infarction with Alteration of Serum NSE, S-100B and Endothelin
Current Neurovascular Research Transient Blood Brain Barrier Disruption Induced by Oleic Acid is Mediated by Nitric Oxide
Current Neurovascular Research